Ryvu Therapeutics

Please note: The information displayed on this page might be outdated.
Ryvu Therapeutics : Developer of targeted oncology therapies hematology/solid tumors. RVU120 is wholly-owned first-in-class oral CDK8/19 inhibitor in Phase I for AML/MDS with start-up of Phase Ib in solid tumors expected 3Q 2021. Company has small molecule, synthetic lethality platform in pre-clinical development including novel targets WRN and PRMT5. Ryvu's PIM/FLT3 kinase inhibitor in Phase 1/2 is partnered with Menarini.
Based in...
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Biotechnology, Pharmaceuticals
Investement Strategy
Under the Radar
Therapeutic Modalities
Gene Therapy, Small Molecule
2 Sternbacha Street
Kraków, 30-394

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • Vatnak Vat-Ho, Chief Business Officer

Top 10 Holders of Ryvu Therapeutics SA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
PTE PZU SA 10.87 1,994,695 0.00 Funds 12/31/21
Norges Bank Investment Management 6.35 1,164,840 0.00 Funds 12/31/21
Aviva PTE Aviva Santander SA 6.12 1,122,859 0.00 Stakes 8/18/21
NN Investment Partners Towarzystwo Funduszy Inwestycyjnych SA 0.05 8,780 0.00 Funds 5/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.